Celon Pharma S.A. (WSE:CLN)

Market Cap	1.17B
Revenue (ttm)	206.22M
Net Income (ttm)	-68.88M
Shares Out	53.86M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	1,947.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,293
Average Volume	8,810
Open	21.35
Previous Close	21.70
Day's Range	21.35 - 21.70
52-Week Range	20.60 - 29.35
Beta	0.68
RSI	44.89
Earnings Date	Nov 19, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 558
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 205.55 million, a decrease of -4.25% compared to the previous year's 214.66 million. Losses were -34.45 million, 22.5% more than in 2023.